The Journal of
Clinical Psychiatry

Empowering mental health professionals with peer-reviewed psychiatric research and insights

Back to top Open menu arrow
Current Issue Digital Edition Archives Authors Reviewers

Page 6

More JCP Articles

JCP
NNT, NNH, and LLH for Aripiprazole Once-Monthly in Schizophrenia
Original Research

NNT, NNH, and LLH for Aripiprazole Once-Monthly in Schizophrenia

May 13, 2026

Data demonstrate a favorable benefit-risk profile for aripiprazole once-monthly 400 vs placebo in acute and maintenance treatment of schizophrenia.
, , , et al
JCP
Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation
Original Research ▶ Video

Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation

May 13, 2026

A single psilocybin dose with psychological support was associated with rapid, large, and durable reductions in suicidal ideation and depressive symptoms.
, , , et al
JCP
Effects of Experimental Intermittent Theta Burst Stimulation on Negative Symptoms of Schizophrenia
Original Research

Effects of Experimental Intermittent Theta Burst Stimulation on Negative Symptoms of Schizophrenia

May 11, 2026

Findings suggest limited efficacy of experimental intermittent theta burst stimulation over the left DLPFC for negative symptoms.
, , , et al
JCP
Catching Cognitive Decline Early with Gary W. Small, MD
Podcast

Catching Cognitive Decline Early with Gary W. Small, MD

May 5, 2026

Dr. Gary W. Small on the continuum of age-related cognitive decline: biomarkers, differential diagnosis, treatment sequencing, and lifestyle interventions for brain health.
,
JCP
CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial
Original Research

CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial

May 4, 2026

In patients with major depression and suicidal ideation, adding a 16-week CBT course to esketamine led to greater improvements in suicidal ideation and depression severity than esketamine alone.
, , , et al
JCP
Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials
Narrative Review

Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials

April 29, 2026

The TDIS followed a similar trajectory to other clinician- and patient-reported outcomes measured in tardive dyskinesia clinical trials, and a change of 4 points in total score is considered…
, , , et al
JCP
The Patient Perspective on Tardive Dyskinesia
Commentary

The Patient Perspective on Tardive Dyskinesia

April 29, 2026

Patients’ perspectives on their experiences with tardive dyskinesia provide critical insights that go beyond the information provided by clinical assessments.
JCP
SSRI, SNRI, or Other Antidepressant Use Not Associated With Differential Outcomes in Ketamine or Esketamine Treatment
Brief Report

SSRI, SNRI, or Other Antidepressant Use Not Associated With Differential Outcomes in Ketamine or Esketamine Treatment

April 27, 2026

No group differences were seen between concurrent oral antidepressant class and clinical outcomes in patients treated with IV ketamine or IN esketamine.
, , , et al
JCP
The Emerging Role of GLP-1s in Psychiatry with Roger S. McIntyre, MD, FRCPC
Podcast

The Emerging Role of GLP-1s in Psychiatry with Roger S. McIntyre, MD, FRCPC

April 21, 2026

GLP-1 receptor agonists in psychiatric care: Dr. Roger McIntyre reviews their neuroscience, clinical applications, safety considerations, and future potential.
,
JCP
Catatonia as a Case Study in Psychiatric Decision-Making
ASCP Corner

Catatonia as a Case Study in Psychiatric Decision-Making

April 20, 2026

Historical approaches to clinical decision-making are discussed, followed by a decision-making matrix that incorporates expected risks and treatment benefits into management decisions.
,
JCP
Phase 2b Study to Evaluate Basmisanil as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia
Original Research

Phase 2b Study to Evaluate Basmisanil as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia

April 15, 2026

Although basmisanil did not improve cognitive deficits, the results offer insight into factors that should facilitate design of more informative trials.
, , , et al
JCP
Suicide Risk and VHA Utilization Among Those with a Suicide Attempt in the US Military
Original Research

Suicide Risk and VHA Utilization Among Those with a Suicide Attempt in the US Military

April 13, 2026

Veterans with a history of suicide attempt prior to transitioning out of military service were more likely to have a suicide attempt or die from suicide after separation than…
, , , et al

Insightful. Evidence-based. Human-centered.

Listen Now
Psychiatrist Steven Berkowitz, MD, discusses psychedelic medicine for trauma treatment

Subscribe to read
more articles

Subscribe